AutoImmune-AIMM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AutoImmune-AIMM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ravi Nayar who wrote (183)	8/4/1997 10:22:00 AM
From: Dr. John M. de Castro	of 298

I would urge caution. The press release is very ambiguous. Nowhere does it mention statistical significance and the MYLORAL results referred to is a subset analysis. You can subdivide patient groups an infinite number of ways until you find one that is different. This can be produced in chance distributions. If the third Phase II trial with COLORAL had been statistically significant the company would have put out a press release on it alone. The fact that they didn't, tells me that it wasn't significant. What they did was combine all of the results from the three Phase II trials and found a suggestion of an effect. Had it been statistically significant, they would have said so. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next